Chemotherapy: Open Access
Open Access

Innovative Methods for Transforming Gynecological Cancers and Prevention

Siyue Jiang^{* *}Correspondence: Siyue Jiang, Department of Obstetrics and Gynecology, University of Lanzhou First Hospital, Gansu, China, Email:

Author info »

Description

Gynecological cancers are a group of cancers that affect the female reproductive system. They include cervical, ovarian, uterine (endometrial), vaginal and vulvar cancers. Gynecological cancer represents a significant global health challenge and conventional treatment modalities have demonstrated limited efficacy [1]. Cervical cancer, often linked to Human Papillomavirus (HPV) infection, remains a leading cause of cancer-related deaths in women, despite the availability of vaccines and screening methods. Endometrial cancer or uterine cancer, primarily affects postmenopausal women and is associated with hormonal imbalances, while vaginal and vulvar cancers, though rarer, also demand attention due to their impact on quality of life and potential for severe complications.

Types of gynecological cancers

Cervical cancer: It is one of the most preventable types of cancer, primarily caused by persistent infection with high-risk types of Human Papillomavirus (HPV) [2].

Symptoms: Abnormal vaginal bleeding, Unusual vaginal discharge, Pelvic pain.

Diagnosis: Pap smear and Human Papillomavirus (HPV) testing, Colposcopy and biopsy for abnormal Pap results, Imaging tests Computed Tomography (CT), Magnetic resonance imaging (MRI), Positron Emission Tomography (PET) scans.

Treatment: Surgery (e.g., hysterectomy), Radiation therapy.

Ovarian cancer: Ovarian cancer often goes undetected until it has spread within the pelvis and abdomen, making it the deadliest of the gynecological cancers.

Symptoms: Bloating, Pelvic or abdominal pain, Difficulty eating or feeling full quickly, Urinary symptoms (urgency or frequency).

Diagnosis: Pelvic examination, Imaging tests (ultrasound, Computed Tomography (CT) scans, Blood tests (CA-125), Biopsy.

Treatment: Surgery (cytoreductive surgery), Chemotherapy, Targeted therapy (PARP inhibitors), Hormone therapy for certain types.

Uterine (Endometrial) cancer: It is the most common gynecological cancer in the United States [3].

Symptoms: Abnormal vaginal bleeding (especially postmenopausal), Pelvic pain, Unusual vaginal discharge.

Diagnosis: Endometrial biopsy, Transvaginal ultrasound, Hysteroscopy, Imaging tests Computed Tomography (CT), Magnetic Resonance Imaging (MRI).

Treatment: Surgery (hysterectomy), Radiation therapy, Chemotherapy, Hormone therapy.

Vaginal cancer: Vaginal cancer is a rare cancer that starts in the vagina [4]. It can be secondary, arising from another gynecological cancer that has spread.

Symptoms: Abnormal vaginal bleeding, Vaginal discharge, Pelvic pain, Lump in the vagina.

Diagnosis: Pelvic examination, Pap smear, Biopsy, Imaging tests Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) scans.

Treatment: Surgery, Radiation therapy, Chemotherapy

Vulvar cancer: Vulvar cancer begins in the external female genitalia. It is also relatively rare and often associated with HPV infection [5].

Symptoms: Persistent itching, Pain or tenderness, Changes in skin color or thickness

Diagnosis: Pelvic examination, Biopsy, Imaging tests (Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) scans.

Treatment: Surgery (vulvectomy), Radiation therapy, Chemotherapy.

Advances in treatment

Recent advances in the treatment of gynecological cancers have significantly improved patient outcomes and quality of life [6]. These innovations include:

Minimally invasive surgery: Laparoscopic and robotic-assisted surgeries have revolutionized the treatment of gynecological cancers. These techniques offer several benefits, including: Smaller incisions, Reduced blood loss, Shorter hospital stays, Faster recovery times.

Targeted therapy: Targeted therapies are designed to attack specific molecules involved in cancer growth and progression [7].

PARP inhibitors: Used in ovarian cancer patients with BRCA mutations, PARP inhibitors block a protein used by cells to repair damaged Deoxyribose Nucleic Acid (DNA), leading to cancer cell death [8].

Bevacizumab: An anti-angiogenesis drug that inhibits the formation of blood vessels that supply nutrients to tumors, used in ovarian and cervical cancers.

Genetic and molecular profiling: Advances in genetic and molecular profiling enable personalized treatment plans [9]. By understanding the genetic makeup of a tumor, oncologists can tailor therapies that are more likely to be effective, reducing trial and error and improving outcomes.

Enhanced screening and prevention: Continued efforts in screening and prevention, including regular Pap smears and Human Papillomavirus (HPV) testing, are important in early detection and treatment of gynecological cancers [10].

Conclusion

Gynecological cancers encompass a diverse group of malignancies affecting the female reproductive system. Early detection through regular screening and awareness of symptoms is critical in improving survival rates. Ongoing study and innovation are essential in the fight against these cancers, underscoring the importance of continued investment in medical science and patient care. Advances in treatment, including targeted therapies and immunotherapies, offer Chemo potential opportunities for better outcomes. Ongoing study and increased awareness are essential to combat these diseases and improve the quality of life for affected women. Collective efforts in education, prevention and innovative treatments are key to addressing the global burden of gynecological cancers.

References

1. Fontham ET, Wolf AM, Church TR, Etzioni R, Flowers CR, Herzig A, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American cancer society. CA Cancer J Clin. 2020;70(5):321-346.

   [Crossref] [Google scholar] [PubMed]

2. Frazer IH, Cox JT, Mayeaux Jr EJ, Franco EL, Moscicki AB, Palefsky JM, et al. Advances in prevention of cervical cancer and other human papillomavirus-related diseases. Pediatr Infect Dis J. 2006;25(2):S65-S81.

   [Crossref] [Google scholar] [PubMed]

3. Rose PG. Endometrial carcinoma. New England Journal of Medicine. 1996;335(9):640-649.

   [Crossref] [Google scholar] [PubMed]

4. Hacker NF, Eifel PJ, van Der Velden J. Cancer of the vagina. Int J Gynaecol Obstet.  2012;131:S84-S87.

   [Crossref] [Google scholar] [PubMed]  

5. Gormley RH, Kovarik CL. Human papillomavirus–related genital disease in the immunocompromised host: Part II. J Am Acad Dermatol. 2012;66(6):867.e1-e14.

   [Crossref] [Google scholar] [PubMed]

6. Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: Current advances and future directions. International journal of medical sciences Int J Med Sci. 2012;9(3):193-199.

   [Crossref] [Google scholar] [PubMed]

7. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther. 2005;16(9):1016-27.

   [Crossref] [Google scholar] [PubMed]

8. Noordermeer SM, van Attikum H. PARP inhibitor resistance: A tug-of-war in BRCA-mutated cells. Trends Cell Biol. 2019;29(10):820-834.

   [Crossref] [Google scholar] [PubMed]

9. Kourou K, Exarchos TP, Exarchos KP, Karamouzis MV, Fotiadis DI. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2015;13:8-17.

   [Crossref] [Google scholar] [PubMed]

10. Comparetto C, Borruto F. Genetic screening of cervical cancer. OBM Genetics. 2021;5(3):1-37.

    [Crossref] [Google scholar]